

Domain Therapeutics achieves multi-target collaboration with Boehringer Ingelheim

30 September 2019 | News

Less than one year after signing an agreement, the orphan GPCRs (G Protein-Coupled Receptors) expert has reached key discovery milestones using its proprietary platforms, DTect-All™ and bioSens-All™



Domain Therapeutics, a biopharmaceutical company specialized in the discovery and development of new drug candidates targeting transmembrane receptors in neurology, oncology and rare diseases, on 30 Sep 2019, announced the achievement of two discovery milestones in its multi-target collaboration with Boehringer Ingelheim.

These milestones illustrate the ability of Domain Therapeutics to address orphan GPCRs (G Protein-Coupled Receptors) using its proprietary platforms, DTect-All™ and bioSens-All™. Financial details were not disclosed.

“Collaborating with a partner of Boehringer Ingelheim's standing is a great opportunity and another excellent endorsement of our expertise with challenging GPCRs,” said Pascal Neuville, CEO of Domain Therapeutics. “We are very proud to have achieved, on time, the two first milestones of this collaboration. We look forward to building on this success.”

The two companies pursue collaboration on the ongoing projects with the final objective to nominate preclinical candidates for the treatment of neuropsychiatric diseases.